Previous studies found that patients with pT1a-bN0, HER2-positive breast cancer had worse disease outcome than HER2-negative diseases21-23, which may indicate potential benefit from adjuvant trastuzumab treatment24-25. Here, ERBB2 is linked to breast carcinoma.